company background image
NSB

NeuroScientific Biopharmaceuticals ASX:NSB Stock Report

Last Price

AU$0.14

Market Cap

AU$20.1m

7D

16.7%

1Y

-58.2%

Updated

02 Dec, 2022

Data

Company Financials
NSB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

NSB Stock Overview

NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies.

NeuroScientific Biopharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NeuroScientific Biopharmaceuticals
Historical stock prices
Current Share PriceAU$0.14
52 Week HighAU$0.38
52 Week LowAU$0.07
Beta0.66
1 Month Change72.84%
3 Month Change-33.33%
1 Year Change-58.21%
3 Year Change-33.33%
5 Year Changen/a
Change since IPO-37.78%

Recent News & Updates

Recent updates

Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?

May 25
Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Jan 27
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

Oct 07
NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Jun 23
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Mar 10
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely

Nov 18
We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely

Shareholder Returns

NSBAU BiotechsAU Market
7D16.7%-0.1%1.3%
1Y-58.2%-2.5%-1.1%

Return vs Industry: NSB underperformed the Australian Biotechs industry which returned -2.5% over the past year.

Return vs Market: NSB underperformed the Australian Market which returned -1.1% over the past year.

Price Volatility

Is NSB's price volatile compared to industry and market?
NSB volatility
NSB Average Weekly Movement23.7%
Biotechs Industry Average Movement8.8%
Market Average Movement9.0%
10% most volatile stocks in AU Market16.0%
10% least volatile stocks in AU Market4.1%

Stable Share Price: NSB is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: NSB's weekly volatility has increased from 15% to 24% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002n/aPaul Renniehttps://www.neuroscientific.com

NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.

NeuroScientific Biopharmaceuticals Limited Fundamentals Summary

How do NeuroScientific Biopharmaceuticals's earnings and revenue compare to its market cap?
NSB fundamental statistics
Market CapAU$20.09m
Earnings (TTM)-AU$10.44m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NSB income statement (TTM)
RevenueAU$0
Cost of RevenueAU$66.72k
Gross Profit-AU$66.72k
Other ExpensesAU$10.37m
Earnings-AU$10.44m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.073
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did NSB perform over the long term?

See historical performance and comparison